公开(公告)号：US20070054842A1

公开(公告)日：2007-03-08

申请号：US11491126

申请日：2006-07-21

Applicant: Lawrence Blatt ,  Scott Seiwert ,  Steven Andrews ,  Pierre Martin ,  Andreas Schumacher ,  Bradley Barnett ,  C. Eary ,  Robert Kaus ,  Timothy Kercher ,  Weidong Liu ,  Michael Lyon ,  Paul Nichols ,  Bin Wang ,  Tarek Sammakia ,  April Kennedy ,  Yutong Jiang

Inventor： Lawrence Blatt ,  Scott Seiwert ,  Steven Andrews ,  Pierre Martin ,  Andreas Schumacher ,  Bradley Barnett ,  C. Eary ,  Robert Kaus ,  Timothy Kercher ,  Weidong Liu ,  Michael Lyon ,  Paul Nichols ,  Bin Wang ,  Tarek Sammakia ,  April Kennedy ,  Yutong Jiang

IPC: A61K38/12

CPC classification number: C07K5/0806 ,  A61K38/00 ,  A61K38/1793 ,  A61K38/212 ,  A61K38/217 ,  A61K38/2292 ,  A61K38/55 ,  C07D471/04 ,  C07D487/04 ,  C07K5/0804 ,  A61K2300/00

Abstract: The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Abstract translation: 实施方案提供通式I至通式VIII的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

公开(公告)号：US20100209391A1

公开(公告)日：2010-08-19

申请号：US12769449

申请日：2010-04-28

Applicant: SCOTT SEIWERT ,  LEONID BEIGELMAN ,  LAWRENCE M. BLATT ,  TIMOTHY KERCHER ,  APRIL L. KENNEDY ,  STEVEN W. ANDREWS

Inventor： SCOTT SEIWERT ,  LEONID BEIGELMAN ,  LAWRENCE M. BLATT ,  TIMOTHY KERCHER ,  APRIL L. KENNEDY ,  STEVEN W. ANDREWS

IPC: A61K31/404 ,  C07D403/12 ,  A61K31/7052 ,  A61K31/427 ,  A61K38/21 ,  A61K31/7072 ,  A61K31/7068 ,  A61P1/16

CPC classification number: C07D403/14 ,  C07D231/56 ,  C07D471/04

Abstract: The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments also provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Abstract translation: 实施方案提供了通式II的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

公开(公告)号：US09562055B2

公开(公告)日：2017-02-07

申请号：US14117615

申请日：2012-05-09

Applicant: Shelley Allen ,  Steven W. Andrews ,  James F. Blake ,  Kevin R. Condroski ,  Julia Haas ,  Lily Huang ,  Yutong Jiang ,  Timothy Kercher ,  Gabrielle R. Kolakowski ,  Jeongbeob Seo

Inventor： Shelley Allen ,  Steven W. Andrews ,  James F. Blake ,  Kevin R. Condroski ,  Julia Haas ,  Lily Huang ,  Yutong Jiang ,  Timothy Kercher ,  Gabrielle R. Kolakowski ,  Jeongbeob Seo

IPC: C07D403/14 ,  C07D407/14 ,  C07D409/14 ,  C07D495/04 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  A61K31/4155 ,  A61K31/4162 ,  A61K31/4178 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377

CPC classification number: C07D403/12 ,  A61K31/4155 ,  A61K31/4162 ,  A61K31/4178 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/048 ,  C07D495/04 ,  Y02A50/414

Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract translation: 其中R1，R2，Ra，Rb，Rc，Rd，X，Y，B和环C如本文所定义的式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂合物或前药，其中 Y-B部分和NH-C（= X）-NH部分是反式构型，是TrkA激酶的抑制剂，可用于治疗可用TrkA激酶抑制剂如疼痛，癌症治疗的疾病 ，炎症，神经变性疾病和某些传染病。

公开(公告)号：US20130131039A1

公开(公告)日：2013-05-23

申请号：US13640099

申请日：2011-04-11

Applicant: Laurence E. Burgess ,  Mark Laurence Boys ,  Robert D. Groneberg ,  Darren M. Harvey ,  Timothy Kercher ,  Christopher F. Kraser ,  Ellen Laird ,  Eugene Tarlton ,  Qian Zhao ,  Lily Huang

Inventor： Laurence E. Burgess ,  Mark Laurence Boys ,  Robert D. Groneberg ,  Darren M. Harvey ,  Timothy Kercher ,  Christopher F. Kraser ,  Ellen Laird ,  Eugene Tarlton ,  Qian Zhao ,  Lily Huang

IPC: C07D487/04 ,  C07D498/04

CPC classification number: C07D487/04 ,  C07D498/04

Abstract: Compounds of Formula I: (Formula should be inserted here) and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, R7, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

Abstract translation: 式I化合物（此处应该插入式）及其其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，X 1和X 2具有本说明书中给出的含义的立体异构体及其药学上可接受的盐和溶剂化物是抑制剂 的一种或多种JAK激酶，并且可用于治疗自身免疫性疾病，炎性疾病，移植器官，组织和细胞的排斥，以及血液系统疾病和恶性肿瘤及其并发症。

公开(公告)号：US07781474B2

公开(公告)日：2010-08-24

申请号：US11773912

申请日：2007-07-05

Applicant: Scott Seiwert ,  Leonid Beigelman ,  Lawrence M. Blatt ,  Timothy Kercher ,  April L. Kennedy ,  Steven W. Andrews

Inventor： Scott Seiwert ,  Leonid Beigelman ,  Lawrence M. Blatt ,  Timothy Kercher ,  April L. Kennedy ,  Steven W. Andrews

IPC: A61K31/40 ,  C07D207/00

CPC classification number: C07D403/14 ,  C07D231/56 ,  C07D471/04

Abstract: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula III, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Abstract translation: 实施方案提供了通式I的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案提供了通式II的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案提供了通式III的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。